North America
Tags: Canada, Life SciencesBy Richard Y. Cheung, Ph.D., Toronto, Fasken Martineau DuMoulin
Due to concerns about the growing percentage of the health care budget allotted to drug spending in Canada and the relative drug prices in Canada compared to other developed countries, the Canadian government is proposing changes to the way in which prices for patented drugs are regulated …
Read or download the full article below.
Latest Updates
Related Articles
Related Articles by Jurisdiction
A change of role for a legal representative under the new Clinical Trials Regulation 536/2014?
The roles and responsibilities of the legal representative set out under Clinical Trials
Directive 2001/20/EC are likely to change under the new Clinical Trials Regulation
536/2014.
Claims that Involve a Fixed Dosage and Schedule Can Constitute Patentable Subject Matter
The Canadian Intellectual Property Office has issued a revised guidance which provides clear instructions on how to approach medical use claims and determine whether such claims are eligible for patent protection.
New challenges for investors in the US – CFIUS
It would be a mistake to underestimate the growing power of CFIUS to regulate foreign investors in US companies.
Latest Articles
